Figure 3 from Auranofin Synergizes with Cisplatin in Reducing Tumor Burden of NOTCH-Dependent Ovarian Cancer
<p>Auranofin increases the overall survival of OVCAR3 CDX mice. <b>A,</b><i>In vivo</i> imaging system spectrum <i>in vivo</i> images of tumor burden. Mice were treated with placebo, cisplatin, auranofin, or both drugs, following the regimen shown. Mice mark...
Saved in:
| 主要作者: | |
|---|---|
| 其他作者: | , , , , |
| 出版: |
2025
|
| 主題: | |
| 標簽: |
添加標簽
沒有標簽, 成為第一個標記此記錄!
|
| _version_ | 1851482133975007232 |
|---|---|
| author | Robert J. Lake (22408833) |
| author2 | Parisa Nikeghbal (22408836) Irina V. Lagutina (15133518) Kimberly K. Leslie (22408839) Mara P. Steinkamp (15136266) Hua-Ying Fan (22408842) |
| author2_role | author author author author author |
| author_facet | Robert J. Lake (22408833) Parisa Nikeghbal (22408836) Irina V. Lagutina (15133518) Kimberly K. Leslie (22408839) Mara P. Steinkamp (15136266) Hua-Ying Fan (22408842) |
| author_role | author |
| dc.creator.none.fl_str_mv | Robert J. Lake (22408833) Parisa Nikeghbal (22408836) Irina V. Lagutina (15133518) Kimberly K. Leslie (22408839) Mara P. Steinkamp (15136266) Hua-Ying Fan (22408842) |
| dc.date.none.fl_str_mv | 2025-10-10T10:00:21Z |
| dc.identifier.none.fl_str_mv | 10.1158/2767-9764.30328485 |
| dc.relation.none.fl_str_mv | https://figshare.com/articles/figure/Figure_3_from_Auranofin_Synergizes_with_Cisplatin_in_Reducing_Tumor_Burden_of_NOTCH-Dependent_Ovarian_Cancer/30328485 |
| dc.rights.none.fl_str_mv | CC BY info:eu-repo/semantics/openAccess |
| dc.subject.none.fl_str_mv | Cancer Therapeutic Research and Development Methods and Technology Combination Chemotherapy Drug Targets Oncoprotein & tumor suppressor drug targets Ovarian Cancer Preclinical Models Organoids Reversal Of Drug Resistance Xenograft Models |
| dc.title.none.fl_str_mv | Figure 3 from Auranofin Synergizes with Cisplatin in Reducing Tumor Burden of NOTCH-Dependent Ovarian Cancer |
| dc.type.none.fl_str_mv | Image Figure info:eu-repo/semantics/publishedVersion image |
| description | <p>Auranofin increases the overall survival of OVCAR3 CDX mice. <b>A,</b><i>In vivo</i> imaging system spectrum <i>in vivo</i> images of tumor burden. Mice were treated with placebo, cisplatin, auranofin, or both drugs, following the regimen shown. Mice marked with a red “X” in week 3 had little-to-no cancer cell uptake and were removed from data analysis in <b>B–G</b>. <b>B,</b> Tumor growth over time shown as mean normalized bioluminescence ± SEM for each treatment group (<i>n</i> = 4 mice per group at baseline). <b>C,</b> Raw <i>P</i> values plotted over time comparing cisplatin monotherapy with auranofin–cisplatin combination treatment. Statistical significance (red dot) was determined using multiple unpaired <i>t</i> tests. <b>D,</b> Magnified view of <b>B</b>, focusing on the cisplatin monotherapy and the combination treatment group (scaled between 0 and 1). <b>E,</b> Tumor burden for individual mice at week 5. Unpaired <i>t</i> tests were used for statistical comparison. <b>F,</b> AUC analysis of normalized tumor burden over time for each treatment group. Both tumor growth and shrinkage phases were quantified. Statistical comparisons were performed using one-way ANOVA with Holm–Šídák multiple comparisons. <b>G,</b> Kaplan–Meier survival analysis of each treatment group using humane endpoints. Statistical significance was determined by unpaired <i>t</i> tests. *, <i>P</i> < 0.05; **, <i>P</i> < 0.01; ****, <i>P</i> < 0.0001.</p> |
| eu_rights_str_mv | openAccess |
| id | Manara_edbc4a1a1d1d110bf5bb9aed3775b716 |
| identifier_str_mv | 10.1158/2767-9764.30328485 |
| network_acronym_str | Manara |
| network_name_str | ManaraRepo |
| oai_identifier_str | oai:figshare.com:article/30328485 |
| publishDate | 2025 |
| repository.mail.fl_str_mv | |
| repository.name.fl_str_mv | |
| repository_id_str | |
| rights_invalid_str_mv | CC BY |
| spelling | Figure 3 from Auranofin Synergizes with Cisplatin in Reducing Tumor Burden of NOTCH-Dependent Ovarian CancerRobert J. Lake (22408833)Parisa Nikeghbal (22408836)Irina V. Lagutina (15133518)Kimberly K. Leslie (22408839)Mara P. Steinkamp (15136266)Hua-Ying Fan (22408842)CancerTherapeutic Research and DevelopmentMethods and TechnologyCombination ChemotherapyDrug TargetsOncoprotein & tumor suppressor drug targetsOvarian CancerPreclinical ModelsOrganoidsReversal Of Drug ResistanceXenograft Models<p>Auranofin increases the overall survival of OVCAR3 CDX mice. <b>A,</b><i>In vivo</i> imaging system spectrum <i>in vivo</i> images of tumor burden. Mice were treated with placebo, cisplatin, auranofin, or both drugs, following the regimen shown. Mice marked with a red “X” in week 3 had little-to-no cancer cell uptake and were removed from data analysis in <b>B–G</b>. <b>B,</b> Tumor growth over time shown as mean normalized bioluminescence ± SEM for each treatment group (<i>n</i> = 4 mice per group at baseline). <b>C,</b> Raw <i>P</i> values plotted over time comparing cisplatin monotherapy with auranofin–cisplatin combination treatment. Statistical significance (red dot) was determined using multiple unpaired <i>t</i> tests. <b>D,</b> Magnified view of <b>B</b>, focusing on the cisplatin monotherapy and the combination treatment group (scaled between 0 and 1). <b>E,</b> Tumor burden for individual mice at week 5. Unpaired <i>t</i> tests were used for statistical comparison. <b>F,</b> AUC analysis of normalized tumor burden over time for each treatment group. Both tumor growth and shrinkage phases were quantified. Statistical comparisons were performed using one-way ANOVA with Holm–Šídák multiple comparisons. <b>G,</b> Kaplan–Meier survival analysis of each treatment group using humane endpoints. Statistical significance was determined by unpaired <i>t</i> tests. *, <i>P</i> < 0.05; **, <i>P</i> < 0.01; ****, <i>P</i> < 0.0001.</p>2025-10-10T10:00:21ZImageFigureinfo:eu-repo/semantics/publishedVersionimage10.1158/2767-9764.30328485https://figshare.com/articles/figure/Figure_3_from_Auranofin_Synergizes_with_Cisplatin_in_Reducing_Tumor_Burden_of_NOTCH-Dependent_Ovarian_Cancer/30328485CC BYinfo:eu-repo/semantics/openAccessoai:figshare.com:article/303284852025-10-10T10:00:21Z |
| spellingShingle | Figure 3 from Auranofin Synergizes with Cisplatin in Reducing Tumor Burden of NOTCH-Dependent Ovarian Cancer Robert J. Lake (22408833) Cancer Therapeutic Research and Development Methods and Technology Combination Chemotherapy Drug Targets Oncoprotein & tumor suppressor drug targets Ovarian Cancer Preclinical Models Organoids Reversal Of Drug Resistance Xenograft Models |
| status_str | publishedVersion |
| title | Figure 3 from Auranofin Synergizes with Cisplatin in Reducing Tumor Burden of NOTCH-Dependent Ovarian Cancer |
| title_full | Figure 3 from Auranofin Synergizes with Cisplatin in Reducing Tumor Burden of NOTCH-Dependent Ovarian Cancer |
| title_fullStr | Figure 3 from Auranofin Synergizes with Cisplatin in Reducing Tumor Burden of NOTCH-Dependent Ovarian Cancer |
| title_full_unstemmed | Figure 3 from Auranofin Synergizes with Cisplatin in Reducing Tumor Burden of NOTCH-Dependent Ovarian Cancer |
| title_short | Figure 3 from Auranofin Synergizes with Cisplatin in Reducing Tumor Burden of NOTCH-Dependent Ovarian Cancer |
| title_sort | Figure 3 from Auranofin Synergizes with Cisplatin in Reducing Tumor Burden of NOTCH-Dependent Ovarian Cancer |
| topic | Cancer Therapeutic Research and Development Methods and Technology Combination Chemotherapy Drug Targets Oncoprotein & tumor suppressor drug targets Ovarian Cancer Preclinical Models Organoids Reversal Of Drug Resistance Xenograft Models |